JP2656958B2 - ホルモン依存性腫瘍治療剤 - Google Patents
ホルモン依存性腫瘍治療剤Info
- Publication number
- JP2656958B2 JP2656958B2 JP63241208A JP24120888A JP2656958B2 JP 2656958 B2 JP2656958 B2 JP 2656958B2 JP 63241208 A JP63241208 A JP 63241208A JP 24120888 A JP24120888 A JP 24120888A JP 2656958 B2 JP2656958 B2 JP 2656958B2
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- methyl
- phenyl
- hydroxy
- dosage unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 40
- 230000001419 dependent effect Effects 0.000 title claims abstract description 11
- 229940088597 hormone Drugs 0.000 title claims abstract description 10
- 239000005556 hormone Substances 0.000 title claims abstract description 10
- 238000011282 treatment Methods 0.000 title abstract description 15
- 150000001875 compounds Chemical group 0.000 claims abstract description 25
- 230000001833 anti-estrogenic effect Effects 0.000 claims abstract description 22
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 17
- 239000000328 estrogen antagonist Substances 0.000 claims description 21
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 17
- 239000003418 antiprogestin Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 229960001603 tamoxifen Drugs 0.000 claims description 8
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- INJBMNNLSBCVGV-QDWSJHPCSA-N (8r,9r,10s,13r)-13-methyl-2,4,5,6,7,8,9,10,11,12-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C([C@@H]12)CC(=O)CC1CC[C@@H]1[C@@H]2CC[C@@]2(C)C1=CC=C2 INJBMNNLSBCVGV-QDWSJHPCSA-N 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 230000001911 anti-progestational effect Effects 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 description 13
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 11
- 239000000262 estrogen Substances 0.000 description 10
- 229940011871 estrogen Drugs 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000003886 aromatase inhibitor Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- JAPHTGCMVDACOL-UHFFFAOYSA-N [3-[1-(3-acetyloxyphenyl)-2-phenylbut-1-enyl]phenyl] acetate Chemical compound C=1C=CC=CC=1C(CC)=C(C=1C=C(OC(C)=O)C=CC=1)C1=CC=CC(OC(C)=O)=C1 JAPHTGCMVDACOL-UHFFFAOYSA-N 0.000 description 5
- 229940046844 aromatase inhibitors Drugs 0.000 description 5
- 229960002903 benzyl benzoate Drugs 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229910002012 Aerosil® Inorganic materials 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000003637 steroidlike Effects 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 102000003998 progesterone receptors Human genes 0.000 description 3
- 108090000468 progesterone receptors Proteins 0.000 description 3
- -1 prop-1-ynyl Chemical group 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 229940122815 Aromatase inhibitor Drugs 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- DKVSUQWCZQBWCP-QAGGRKNESA-N androsta-1,4,6-triene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C=CC2=C1 DKVSUQWCZQBWCP-QAGGRKNESA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 239000012520 frozen sample Substances 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- PCGSYETZIQUCIO-AABGKKOBSA-N (8S,13S,14S)-13-prop-2-ynyl-2,6,7,8,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one Chemical compound C(#C)C[C@@]12CCC[C@H]1[C@@H]1CCC3=CC(CCC3=C1CC2)=O PCGSYETZIQUCIO-AABGKKOBSA-N 0.000 description 1
- DOBRBVQKUXYHER-ORZNMBHWSA-N (8r,9s,10r,13s,14s)-13-ethyl-10-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](CC)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DOBRBVQKUXYHER-ORZNMBHWSA-N 0.000 description 1
- RSPINGMAWKOXBT-BZGHQHJYSA-N (8r,9s,13s,14s,16s,17s)-16-ethyl-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1C[C@H](CC)[C@H](O)[C@@]1(C)CC2 RSPINGMAWKOXBT-BZGHQHJYSA-N 0.000 description 1
- JQKMNNYZQUQIJJ-UHFFFAOYSA-N 1,1-diphenylbut-1-en-2-ylbenzene Chemical compound C=1C=CC=CC=1C(CC)=C(C=1C=CC=CC=1)C1=CC=CC=C1 JQKMNNYZQUQIJJ-UHFFFAOYSA-N 0.000 description 1
- PJMNEPMSGCRSRC-IEVKOWOJSA-N 4-androstene-3,6,17-trione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=O)C2=C1 PJMNEPMSGCRSRC-IEVKOWOJSA-N 0.000 description 1
- OSVMTWJCGUFAOD-UHFFFAOYSA-N 4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1O OSVMTWJCGUFAOD-UHFFFAOYSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 description 1
- 241001649081 Dina Species 0.000 description 1
- KDYQVUUCWUPJGE-UHFFFAOYSA-N Ethamoxytriphetol Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(O)(C=1C=CC=CC=1)CC1=CC=C(OC)C=C1 KDYQVUUCWUPJGE-UHFFFAOYSA-N 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 241000388430 Tara Species 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- XDFORSMZCYHNBG-UHFFFAOYSA-N benzonitrile;hydrochloride Chemical compound Cl.N#CC1=CC=CC=C1 XDFORSMZCYHNBG-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000044 progesterone antagonist Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873733478 DE3733478A1 (de) | 1987-10-01 | 1987-10-01 | Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore |
| DE3733478.6 | 1987-10-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01106822A JPH01106822A (ja) | 1989-04-24 |
| JP2656958B2 true JP2656958B2 (ja) | 1997-09-24 |
Family
ID=6337559
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63241208A Expired - Fee Related JP2656958B2 (ja) | 1987-10-01 | 1988-09-28 | ホルモン依存性腫瘍治療剤 |
| JP63241207A Expired - Fee Related JP2620333B2 (ja) | 1987-10-01 | 1988-09-28 | 抗ゲスターゲンおよび抗エストロゲン作用を有する化合物を含有する分娩誘発および妊娠中絶のためおよび子宮内膜症および月経困難症の治療のための薬剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63241207A Expired - Fee Related JP2620333B2 (ja) | 1987-10-01 | 1988-09-28 | 抗ゲスターゲンおよび抗エストロゲン作用を有する化合物を含有する分娩誘発および妊娠中絶のためおよび子宮内膜症および月経困難症の治療のための薬剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US4888331A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0310541B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2656958B2 (cg-RX-API-DMAC7.html) |
| AT (2) | ATE83149T1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU616208B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA1329126C (cg-RX-API-DMAC7.html) |
| DE (3) | DE3733478A1 (cg-RX-API-DMAC7.html) |
| DK (2) | DK550188A (cg-RX-API-DMAC7.html) |
| ES (2) | ES2053795T3 (cg-RX-API-DMAC7.html) |
| GR (1) | GR3007225T3 (cg-RX-API-DMAC7.html) |
| IE (2) | IE66335B1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL87885A (cg-RX-API-DMAC7.html) |
| PH (1) | PH26774A (cg-RX-API-DMAC7.html) |
| ZA (2) | ZA887379B (cg-RX-API-DMAC7.html) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2654337B1 (fr) * | 1989-11-15 | 1994-08-05 | Roussel Uclaf | Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant. |
| DE4329344A1 (de) * | 1993-08-27 | 1995-03-02 | Schering Ag | Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri |
| DE4335876A1 (de) * | 1993-10-17 | 1995-04-20 | Schering Ag | Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen |
| GB9410533D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | In situ hybridisation and immuno-Chemical localisation of a growth factor |
| DE4426601A1 (de) * | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
| ZA9510926B (en) | 1994-12-23 | 1996-07-03 | Schering Ag | Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception |
| DE19706061A1 (de) | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
| US6653297B1 (en) * | 1997-07-03 | 2003-11-25 | Medical College Of Hampton Roads | Control of selective estrogen receptor modulators |
| DE19739916C2 (de) * | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
| US6380235B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Benzimidazolones and analogues |
| US6444668B1 (en) | 1999-05-04 | 2002-09-03 | Wyeth | Combination regimens using progesterone receptor modulators |
| US6339098B1 (en) | 1999-05-04 | 2002-01-15 | American Home Products Corporation | 2,1-benzisothiazoline 2,2-dioxides |
| US6306851B1 (en) | 1999-05-04 | 2001-10-23 | American Home Products Corporation | Cyclocarbamate and cyclic amide derivatives |
| AU4980100A (en) * | 1999-05-04 | 2000-11-17 | American Home Products Corporation | Compositions containing benzimidazolones and progestogens |
| US6380178B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Cyclic regimens using cyclocarbamate and cyclic amide derivatives |
| US6319912B1 (en) * | 1999-05-04 | 2001-11-20 | American Home Products Corporation | Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides |
| US6329416B1 (en) | 1999-05-04 | 2001-12-11 | American Home Products Corporation | Combination regimens using 3,3-substituted indoline derivatives |
| US6358947B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Tetracyclic progesterone receptor modulator compounds and methods |
| US6417214B1 (en) | 1999-05-04 | 2002-07-09 | Wyeth | 3,3-substituted indoline derivatives |
| US6399593B1 (en) * | 1999-05-04 | 2002-06-04 | Wyeth | Cyclic regimens using cyclic urea and cyclic amide derivatives |
| US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
| US6355648B1 (en) | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
| US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
| US6369056B1 (en) | 1999-05-04 | 2002-04-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
| US6498154B1 (en) * | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
| EP1173210B1 (en) * | 1999-05-04 | 2004-09-15 | Wyeth | Contraceptive compositions containing antiprogestinic and progestinic |
| US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
| US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6423699B1 (en) | 1999-05-04 | 2002-07-23 | American Home Products Corporation | Combination therapies using benzimidazolones |
| US6407101B1 (en) * | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
| DE60021720T2 (de) | 1999-05-04 | 2006-06-01 | Strakan International Ltd. | Androgen glykoside und die androgenische aktivität davon |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| JP2004510994A (ja) * | 2000-10-06 | 2004-04-08 | バイオメディシンズ，インコーポレイティド | エストロゲン−感受性疾病の処理のための組み合わせ治療 |
| AU1824302A (en) * | 2000-10-18 | 2002-04-29 | Schering Ag | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| US6599921B2 (en) | 2001-02-22 | 2003-07-29 | Nanodesign, Inc. | Non-steroidal estrogen receptor ligands |
| UY27301A1 (es) * | 2001-05-25 | 2003-02-28 | Schering Ag | Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata |
| US20030013694A1 (en) * | 2001-05-25 | 2003-01-16 | Jens Hoffmann | Use and compositions of antiprogestins for treatment of prostate diseases |
| GB0120147D0 (en) * | 2001-08-17 | 2001-10-10 | Metris Therapeutics Ltd | Treatment method |
| DE10159217A1 (de) * | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
| AU2004218474A1 (en) * | 2003-02-28 | 2004-09-16 | Dekk-Tec, Inc. | Resonance modulator for diagnosis and therapy |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| JP2008515811A (ja) * | 2004-10-04 | 2008-05-15 | ウェイン ステイト ユニヴァーシティ | 子宮外妊娠の治療のためのアロマターゼ阻害薬の使用方法 |
| WO2008019048A1 (en) * | 2006-08-04 | 2008-02-14 | Meditrina Pharmaceuticals | Use of aromatase inhibitors for thining the endometrium or treating menorrhagia |
| US7694688B2 (en) | 2007-01-05 | 2010-04-13 | Applied Materials, Inc. | Wet clean system design |
| WO2009075838A2 (en) * | 2007-12-10 | 2009-06-18 | Meditrina Pharmaceuticals, Inc. | Treatment of menorrhagia with aromatase inhibitor |
| US20100087402A1 (en) * | 2008-09-29 | 2010-04-08 | Vivus, Inc. | Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656187A (en) * | 1981-08-03 | 1987-04-07 | Eli Lilly And Company | Treatment of mammary cancer |
| IL68222A (en) * | 1983-03-24 | 1987-02-27 | Yeda Res & Dev | Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity |
| DE3323321A1 (de) * | 1983-06-24 | 1985-01-03 | Schering AG, 1000 Berlin und 4709 Bergkamen | Prophylaxe und therapie von koronaren herzkrankheiten durch senkung des oestrogenspiegels |
| DE3337450A1 (de) * | 1983-10-12 | 1985-04-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | Prostaglandine und antigestagene fuer den schwangerschaftsabbruch |
| GB8327256D0 (en) * | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| US4760053A (en) * | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
| US4775660A (en) * | 1984-08-02 | 1988-10-04 | Fernand Labrie | Treatment of breast cancer by combination therapy |
| US4666885A (en) * | 1985-02-08 | 1987-05-19 | Fernand Labrie | Combination therapy for treatment of female breast cancer |
| ATE75947T1 (de) * | 1984-08-02 | 1992-05-15 | Labrie Fernand | Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs. |
| US4732904A (en) * | 1984-12-24 | 1988-03-22 | Morgan Lee R | Antiestrogenic hydrazones |
| DE3533175A1 (de) * | 1985-09-13 | 1987-03-19 | Schering Ag | Antigestagene zur verschiebung der endometrialen reifung |
| FR2598083B1 (fr) * | 1986-05-05 | 1989-12-29 | Theramex Laboratoire | Nouvelles compositions pharmaceutiques a action antiprogesteronique et leur procede d'obtention |
| DE3633244A1 (de) * | 1986-09-26 | 1988-03-31 | Schering Ag | Antigestagene zur hemmung der uterinen prostaglandinsynthese |
-
1987
- 1987-10-01 DE DE19873733478 patent/DE3733478A1/de not_active Withdrawn
-
1988
- 1988-09-28 JP JP63241208A patent/JP2656958B2/ja not_active Expired - Fee Related
- 1988-09-28 JP JP63241207A patent/JP2620333B2/ja not_active Expired - Fee Related
- 1988-09-30 DE DE8888730221T patent/DE3876582D1/de not_active Expired - Lifetime
- 1988-09-30 AU AU23322/88A patent/AU616208B2/en not_active Ceased
- 1988-09-30 CA CA000579023A patent/CA1329126C/en not_active Expired - Fee Related
- 1988-09-30 IL IL87885A patent/IL87885A/xx active Protection Beyond IP Right Term
- 1988-09-30 EP EP88730221A patent/EP0310541B1/de not_active Expired - Lifetime
- 1988-09-30 DK DK550188A patent/DK550188A/da not_active Application Discontinuation
- 1988-09-30 PH PH37621A patent/PH26774A/en unknown
- 1988-09-30 ZA ZA887379A patent/ZA887379B/xx unknown
- 1988-09-30 AT AT88730221T patent/ATE83149T1/de not_active IP Right Cessation
- 1988-09-30 AU AU23321/88A patent/AU624082B2/en not_active Ceased
- 1988-09-30 CA CA000579022A patent/CA1330039C/en not_active Expired - Fee Related
- 1988-09-30 ES ES88730221T patent/ES2053795T3/es not_active Expired - Lifetime
- 1988-09-30 IE IE295488A patent/IE66335B1/en not_active IP Right Cessation
- 1988-09-30 ES ES88730222T patent/ES2055745T3/es not_active Expired - Lifetime
- 1988-09-30 IL IL87886A patent/IL87886A/xx active Protection Beyond IP Right Term
- 1988-09-30 ZA ZA887378A patent/ZA887378B/xx unknown
- 1988-09-30 DE DE3850026T patent/DE3850026D1/de not_active Expired - Lifetime
- 1988-09-30 AT AT88730222T patent/ATE106730T1/de not_active IP Right Cessation
- 1988-09-30 DK DK550088A patent/DK550088A/da not_active Application Discontinuation
- 1988-09-30 IE IE295388A patent/IE65165B1/en not_active IP Right Cessation
- 1988-10-03 US US07/252,299 patent/US4888331A/en not_active Expired - Lifetime
-
1993
- 1993-03-05 GR GR920402867T patent/GR3007225T3/el unknown
-
1994
- 1994-02-14 US US08/195,046 patent/US5733902A/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2656958B2 (ja) | ホルモン依存性腫瘍治療剤 | |
| JP3441459B2 (ja) | ホルモン補充のための薬剤の調整方法 | |
| Kuhl | Pharmacology of estrogens and progestogens: influence of different routes of administration | |
| Sitruk-Ware et al. | Oral micronized progesterone: Bioavailability pharmacokinetics, pharmacological and therapeutic implications—A review | |
| US5545634A (en) | Activation of androgen receptors with low dose non-masculinizing androgenic compounds | |
| US8426394B2 (en) | Progesterone antagonists such as CDB-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer, etc | |
| JP2002541126A (ja) | 低用量エストロゲン断続的ホルモン補充療法 | |
| KR20090067198A (ko) | 자궁내막 증식을 억제하는 조성물과 방법 | |
| Ottosson | Oral progesterone and estrogen/progestogen therapy: effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins | |
| EP0310542B1 (de) | Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren | |
| Sitruk-Ware | Hormonal replacement therapy | |
| Sitruk-Ware | Hormone therapy and the cardiovascular system: the critical role of progestins | |
| WO1995005828A1 (de) | PROGESTERONANTAGONISTISCH- UND ANTIÖSTROGEN WIRKSAME VERBINDUNGEN FÜR DIE BEHANDLUNG DES $i(LEIOMYOMATA UTERI) | |
| EP0399631B1 (en) | Use of gestodene for the production of pharmaceutical agents | |
| KR100729311B1 (ko) | 호르몬 대체 요법(ｈｒｔ)용 조성물의 성분으로서의메조프로게스틴 (프로게스테론 수용체 조절물질) | |
| JP2716461B2 (ja) | プロゲステロン合成阻害剤及び抗ゲスタゲンを含有する医薬及びその製法 | |
| Sobel | Progestins in preventive hormone therapy: including pharmacology of the new progestins, desogestrel, norgestimate, and gestodene: are there advantages? | |
| US20010056086A1 (en) | Use of anti-oestrogens as male contraceptives | |
| Sorbera et al. | Trimegestone | |
| Kuhl et al. | Prodrug versus Drug Effects of 150 μg Desogestrel or 3-Keto-Desogestrel in Combination with 30 μg Ethinylestradiol on Hormonal Parameters: Relevance of the Peak Serum Level of 3-Keto-Desogestrel | |
| Sitruk-Ware | Progestins and the cardiovascular system | |
| CA2067173A1 (en) | Use of antigestagens for the production of pharmaceutical agents | |
| US7629334B1 (en) | Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT) | |
| Teichmann | Pharmacology of female sex hormones with respect to lipid and lipoprotein metabolism | |
| Siseles et al. | Hormone replacement therapy and lipid profile: effects of |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |